Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis: A Cohort Study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background: Low-dose glucocorticoids are frequently used for the management of rheumatoid arthritis (RA) and other chronic conditions, but the safety of long-term use remains uncertain. Objective: To quantify the risk for hospitalized infection with long-term use of low-dose glucocorticoids in patients with RA receiving stable disease-modifying antirheumatic drug (DMARD) therapy. Design: Retrospective cohort study. Setting: Medicare claims data and Optum's deidentified Clinformatics Data Mart database from 2006 to 2015. Patients: Adults with RA receiving a stable DMARD regimen for more than 6 months. Measurements: Associations between glucocorticoid dose (none, ≤5 mg/d, >5 to 10 mg/d, and >10 mg/d) and hospitalized infection were evaluated using inverse probability–weighted analyses, with 1-year cumulative incidence predicted from weighted models. Results: 247 297 observations were identified among 172 041 patients in Medicare and 58 279 observations among 44 118 patients in Optum. After 6 months of stable DMARD use, 47.1% of Medicare patients and 39.5% of Optum patients were receiving glucocorticoids. The 1-year cumulative incidence of hospitalized infection in Medicare patients not receiving glucocorticoids was 8.6% versus 11.0% (95% CI, 10.6% to 11.5%) for glucocorticoid dose of 5 mg or less per day, 14.4% (CI, 13.8% to 15.1%) for greater than 5 to 10 mg/d, and 17.7% (CI, 16.5% to 19.1%) for greater than 10 mg/d (all P < 0.001 vs. no glucocorticoids). The 1-year cumulative incidence of hospitalized infection in Optum patients not receiving glucocorticoids was 4.0% versus 5.2% (CI, 4.7% to 5.8%) for glucocorticoid dose of 5 mg or less per day, 8.1% (CI, 7.0% to 9.3%) for greater than 5 to 10 mg/d, and 10.6% (CI, 8.5% to 13.2%) for greater than 10 mg/d (all P < 0.001 vs. no glucocorticoids). Limitation: Potential for residual confounding and misclassification of glucocorticoid dose. Conclusion: In patients with RA receiving stable DMARD therapy, glucocorticoids were associated with a dose-dependent increase in the risk for serious infection, with small but significant risks even at doses of 5 mg or less per day. Clinicians should balance the benefits of low-dose glucocorticoids with this potential risk. Primary Funding Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additional studies have corroborated these findings, linking even low dose glucocorticoid use (prednisone 2.5-7.5 mg/day) to increased risks of cardiovascular disease (9), severe infections (10), hypertension (11), diabetes (12), osteoporosis and fractures (13, 14), and increased overall mortality with concurrent type 2 diabetes mellitus (15).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796 · cited 1×
“Propensity scores were used to create stabilized inverse probability treatment weights (26–28) truncated at the first and 99th percentiles (29).”
Method2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Self-citationSmolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057 · cited 5×
“They are widely accepted for short-term use as bridging therapy in patients starting or changing treatment with DMARDs (4, 5), with the goal of their eventual withdrawal.”
BackgroundInfluentialA tutorial on propensity score estimation for multiple treatments using generalized boosted models
McCaffrey, D. F., Griffin, B. A., Almirall, D., Slaughter, M. E., Ramchand, R., & Burgette, L. F. (2013) · Statistics in Medicine · doi:10.1002/sim.5753 · Cited by 1,450
A combined comorbidity score predicted mortality in elderly patients better than existing scores
Gagne, J. J., Glynn, R. J., Avorn, J., Levin, R., & Schneeweiss, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.10.004 · Cited by 995 · cited 2×
“Covariates measured during the baseline period included age, sex, race, geographic region, calendar year, comorbidities, an adaption of the Charlson Comorbidity Index (23), health care use (outpatient visits, rheumatologist outpatient visits, emergency department visits, and hospitalizations), previous hospitalized in…”
BackgroundSchneeweiss, S. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1200 · Cited by 727 · cited 1×
“To assess the effect of an unmeasured confounder (disease activity) on results, we did a residual bias assessment (30) using C-reactive protein (CRP) level in a subset of patients in Optum.”
MethodSingh, J. A., Cameron, C., Noorbaloochi, S., Cullis, T., Tucker, M., Christensen, R., Ghogomu, E. T., Coyle, D., Clifford, T., Tugwell, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61704-9 · Cited by 623
Wolfe, F., Caplan, L., & Michaud, K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21568 · Cited by 480
Curtis, J. R., Patkar, N., Xie, A., Martin, C., Allison, J. J., Saag, M., Shatin, D., & Saag, K. G. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22504 · Cited by 398 · cited 1×
“The primary outcome definition was the presence of an ICD-9 diagnosis of infection (Supplement Table 1) in any position of the discharge diagnoses from an acute care hospitalization (positive predictive value >80%) (13, 22).”
BackgroundSelf-citationGrijalva, C. G., Chen, L., Delzell, E., Baddley, J. W., Beukelman, T., Winthrop, K. L., Griffin, M. R., Herrinton, L. J., Liu, L., Ouellet-Hellstrom, R., et al. (2011) · JAMA · doi:10.1001/jama.2011.1692 · Cited by 350
Self-citationSvensson, B., Boonen, A., Albertsson, K., van der Heijde, D., Keller, C., Hafström, I., & for the BARFOT Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21298 · Cited by 349
Dixon, W. G., Abrahamowicz, M., Beauchamp, M.-E., Ray, D. W., Bernatsky, S., Suissa, S., & Sylvestre, M.-P. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200702 · Cited by 339
Au, K., Reed, G., Curtis, J. R., Kremer, J. M., Greenberg, J. D., Strand, V., & Furst, D. E. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.128637 · Cited by 337
Self-citationBakker, M. F., Jacobs, J. W. G., Welsing, P. M. J., Verstappen, S. M. M., Tekstra, J., Ton, E., Geurts, M. A. W., van der Werf, J. H., van Albada-Kuipers, G. A., Jahangier-de Veen, Z. N., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-5-201203060-00004 · Cited by 322
Schneeweiss, S., Setoguchi, S., Weinblatt, M. E., Katz, J. N., Avorn, J., Sax, P. E., Levin, R., & Solomon, D. H. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22600 · Cited by 302 · cited 1×
“The primary outcome definition was the presence of an ICD-9 diagnosis of infection (Supplement Table 1) in any position of the discharge diagnoses from an acute care hospitalization (positive predictive value >80%) (13, 22).”
BackgroundThe risk of hospitalized infection in patients with rheumatoid arthritis.
Smitten, A. L., Choi, H. K., Hochberg, M. C., Suissa, S., Simon, T. A., Testa, M. A., & Chan, K. A. (2008) · PubMed · Cited by 281
Validation of rheumatoid arthritis diagnoses in health care utilization data
Kim, S. Y., Servi, A., Polinski, J. M., Mogun, H., Weinblatt, M. E., Katz, J. N., & Solomon, D. H. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3260 · Cited by 228 · cited 1×
“xx) at least 7 days apart, and were receiving a DMARD (20).”
BackgroundSpreeuwenberg, M. D., Bartak, A., Croon, M. A., Hagenaars, J. A., Busschbach, J. J. V., Andrea, H., Twisk, J., & Stijnen, T. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181c1328f · Cited by 227 · cited 1×
“To account for potential confounders, generalized propensity scores based on the probability of being in each exposure group were generated separately in each cohort using multinomial logistic regression models (25, 26) (included variables are shown in Supplement Tables 2 and 3, available at Annals.”
MethodLow-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)
Buttgereit, F., Mehta, D., Kirwan, J., Szechinski, J., Boers, M., Alten, R. E., Supronik, J., Szombati, I., Romer, U., Witte, S., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201067 · Cited by 191
Austin, P. C., & Schuster, T. (2016) · Statistical Methods in Medical Research · doi:10.1177/0962280213519716 · Cited by 191
Generalized propensity score for estimating the average treatment effect of multiple treatments
Feng, P., Zhou, X., Zou, Q., Fan, M., & Li, X. (2012) · Statistics in Medicine · doi:10.1002/sim.4168 · Cited by 180 · cited 1×
“To account for potential confounders, generalized propensity scores based on the probability of being in each exposure group were generated separately in each cohort using multinomial logistic regression models (25, 26) (included variables are shown in Supplement Tables 2 and 3, available at Annals.”
MethodCorticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes.
Caplan, L., Wolfe, F., RUSSELL, A. S., & Michaud, K. D. (2007) · PubMed · Cited by 127
Wilson, J. C., Sarsour, K., Gale, S., Pethö‐Schramm, A., Jick, S. S., & Meier, C. R. (2019) · Arthritis Care & Research · doi:10.1002/acr.23611 · Cited by 111 · cited 1×
“We did not evaluate the risks for other adverse outcomes (for example, fracture, cataracts, diabetes, and cardiovascular events), which have been associated with low-dose glucocorticoids in some studies (18).”
BackgroundCannon, G. W., Mikuls, T. R., Hayden, C. L., Ying, J., Curtis, J. R., Reimold, A. M., Caplan, L., Kerr, G. S., Richards, J. S., Johnson, D. S., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20629 · Cited by 93 · cited 1×
“Continuous use was defined as no gaps in treatment greater than 90 days based on the days' supply from prescription fills or expected infusion intervals for infused therapies (21).”
BackgroundSelf-citationCurrent use of glucocorticoids in patients with rheumatoid arthritis in Germany
Thiele, K., Buttgereit, F., Huscher, D., Zink, A., & Centres, T. G. C. A. (2005) · Arthritis Care & Research · doi:10.1002/art.21467 · Cited by 61
Weaver, A. L., Troum, O. M., Hooper, M. M., Koenig, A. S., Chaudhari, S., Feng, J., & Wenkert, D. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.121288 · Cited by 54
Palmowski, Y., Buttgereit, T., Dejaco, C., Bijlsma, J. W. J., Matteson, E. L., Voshaar, M., Boers, M., & Buttgereit, F. (2017) · Arthritis Care & Research · doi:10.1002/acr.23185 · Cited by 53 · cited 1×
“Controversy over the appropriate use of long-term glucocorticoids stems from continued uncertainty about the safety of low-dose therapy (10).”
BackgroundMakol, A., Davis, J. M., Crowson, C. S., Therneau, T. M., Gabriel, S. E., & Matteson, E. L. (2014) · Arthritis Care & Research · doi:10.1002/acr.22365 · Cited by 38
Wallace, B. I., Lin, P., Kamdar, N. S., Noureldin, M., Hayward, R. A., Fox, D. A., Curtis, J. R., Saag, K. G., & Waljee, A. K. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.09.002 · Cited by 35
Self-citationBiologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis
George, M., Sauer, B. C., Teng, C., Cannon, G. W., England, B. R., Kerr, G. S., Mikuls, T. R., & Baker, J. F. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.180178 · Cited by 29 · cited 1×
“Indeed, older patients and patients with comorbidities are less likely to receive biologics but are equally likely to receive glucocorticoids for their RA (32).”
BackgroundSelf-citation
Cited by
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Hellmich, B., Sanchez-Alamo, B., Schirmer, J. H., Berti, A., Blockmans, D., Cid, M. C., Holle, J. U., Hollinger, N., Karadag, O., Kronbichler, A., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223764 · Cited by 768
Rheumatoid Arthritis — Common Origins, Divergent Mechanisms
Gravallese, E. M., & Firestein, G. S. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2103726 · Cited by 752
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
“However, several retrospective studies have suggested that lower doses ( ≤ 5 mg PE/day) are also associated with a clinically meaningful increase in serious infection risk (388, 390, 394), especially when given for a prolonged duration ( > 3 months) (391).”
BackgroundBeuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 156
Metadata
- Authors
- George, M. D., Baker, J. F., Winthrop, K., Hsu, J. Y., Wu, Q., Chen, L., Xie, F., Yun, H., & Curtis, J. R.
- Affiliations
- University of Pennsylvania (US)
- Philadelphia VA Medical Center (US)
- Oregon Health & Science University (US)
- University of Alabama at Birmingham (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-12-01
- Volume
- 173
- Issue
- 11
- Pages
- 870-878
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC8073808
- OpenAlex
- W3087498606
- Cited by
- 198
- References
- 30
- Citations by year
- 2026: 35 · 2025: 33 · 2024: 32 · 2023: 38 · 2022: 38 · 2021: 19 · 2020: 3
- FWCI
- 18.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (1K23AR073931-01)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- rheumatoid arthritis, low-dose glucocorticoids, hospitalized infection, infection risk, disease-modifying antirheumatic drugs, glucocorticoid dose, long-term glucocorticoid use, adverse drug reactions, Medicare beneficiaries, cumulative incidence, inverse probability weighting, propensity score matching, immunosuppression
- MeSH terms
- Aged, Arthritis, Rheumatoid, Female, Glucocorticoids, Hospitalization, Humans, Infections, Male, Retrospective Studies, Risk Factors, Antirheumatic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.